Costs and Healthcare Resource Utilization for Obstructive Hypertrophic Cardiomyopathy With Septal Reduction Therapy

Clinical Profile of Patients Hospitalized for Heart Failure with Severely Reduced Ejection Fraction: From the GWTG-HF Registry

Healthcare Resource Use, Early Benefit, and Cost for North American Patients with HFrEF Most Likely to Benefit from Omecamtiv Mecarbil

Prevalence and Excess Risk of Hospitalization in Heart Failure with Reduced Ejection Fraction

Characterizing Hospitalization as an Outcome Measure in ALS Clinical Trials

Healthcare Resource Use, Intensity, and Costs Among Patients with Heart Failure with Reduced Ejection Fraction Treated with Omecamtiv Mecarbil in GALACTIC-HF

Adverse Drug Effects Across Patients With Heart Failure: A Systematic Review

Managing the Economic Challenges in the Treatment of Heart Failure

Clinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based Claims Analysis)

Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event